stockportfolio.pro
Stocks / ANIP vs ASTH
ANIP vs ASTH
ANI Pharmaceuticals, Inc. and Astrana Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ANI Pharmaceuticals, Inc. (ANIP) | Astrana Health, Inc. (ASTH) | |
|---|---|---|
| Market cap | $1.8B | $1.9B |
| Revenue (latest FY) | $883.37M | $3.18B |
| Net income (latest FY) | $77.18M | $22.49M |
| Revenue growth (5y CAGR) | 33.5% | 35.9% |
| Net margin | 8.7% | 0.7% |
| Return on equity | 14.3% | 2.9% |
| P/E ratio | 20.8 | 62.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANIP — free Open ASTH — freeFrequently asked questions
Which is bigger, ANIP or ASTH?
Astrana Health, Inc. is larger by market capitalization — $1.9B versus $1.8B.
Which grows faster, ANIP or ASTH?
Over the last five fiscal years, Astrana Health, Inc. grew revenue faster — 35.9%/yr versus 33.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.